A practical reference on GHRH receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-04. Anything still debated is marked as such rather than presented as settled.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
== Further reading == De Iuliis, Gerardo; Pulerà, Dino (2019). "Vertebrates and Their Kin". The Dissection of Vertebrates. pp. 1–44. doi:10.1016/B978-0-12-410460-0.00001-2. ISBN 978-0-12-410460-0. Myomeres are the segmented paired muscular blocks that extend through the trunk and tail. Alternating contraction of the musculature of the right and left sides of the body exerts forces on the notochord, noted earlier as a laterally flexible rod, that allow the side-to-side locomotory movements characteristic of less derived chordates and vertebrates. Johnston, I.A. (2008). "The biological basis of variability in the texture of fish flesh". Improving Seafood Products for the Consumer. pp. 465–489. doi:10.1533/9781845694586.5.465. ISBN 978-1-84569-019-9. The fillet is made up of segmentally arranged structures called myotomes or myomeres, the shape of which varies along the length of the body. In three dimensions, the myomeres constitute a series of overlapping cones that are bounded by connective tissue sheets or myocommata called myosepta. Typically, a transverse steak through the fillet will cut through several myotomes at different levels. Each myotome contains a lateral superficial strip of dark muscle primarily composed of slow contracting fibre types that are used for sustained swimming activity (Johnston et al., 1977).
=== Animal model === Research into malignant hyperthermia was limited until the discovery of "porcine stress syndrome" (PSS) in Danish Landrace and other pig breeds selected for muscling, a condition in which stressed pigs develop "pale, soft, exudative" flesh (a manifestation of the effects of malignant hyperthermia) rendering their meat less marketable at slaughter. This "awake triggering" was not observed in humans, and initially cast doubts on the value of the animal model, but subsequently, susceptible humans were discovered to "awake trigger" (develop malignant hyperthermia) in stressful situations. This supported the use of the pig model for research. Pig farmers use halothane cones in swine yards to expose piglets to halothane. Those that die were MH-susceptible, thus saving the farmer the expense of raising a pig whose meat he would not be able to market. This also reduced the use of breeding stock carrying the genes for PSS. The condition in swine is also due to a defect in ryanodine receptors. Gillard et al. discovered the causative mutation in humans only after similar mutations had first been described in pigs. Horses also develop malignant hyperthermia. A causative mutated allele, ryanodine receptor 1 gene (RyR1) at nucleotide C7360G, generating a R2454G amino acid substitution. has been identified in the American Quarter Horse and breeds with Quarter Horse ancestry, inherited as an autosomal dominant. It can be caused by overwork, anesthesia, or stress. In dogs, its inheritance is autosomal recessive.
The 8th district includes most of the northern and northwestern exurbs of Houston, including Conroe, part of Huntsville, Willis, Magnolia, Brookshire and Hempstead, along with parts of west Houston including Briar Forest, the western end of the Energy Corridor and most of the Bear Creek and Addicks areas in west Harris County. The incumbent is Republican Morgan Luttrell, who was elected with 68.2% of the vote in 2024. Luttrell is not seeking reelection in the heavily Republican district, which gave Donald Trump 63.2% and Ted Cruz 60.1% of the vote in 2024 and is a plurality White district with a 31.3% Hispanic voting age population.
After assuming the presidency, Lula made his first international trip as president to Buenos Aires, where he announced that Brazil would resume its relations with Latin America and that the government would be willing to finance infrastructure works in neighbouring countries through the BNDES again. Lula also defended the construction of a gas pipeline between Brazil and Argentina to transport the shale gas extracted in the Vaca Muerta field. The idea was criticized by some experts, as the project may cause damage to the region's environment. The announcement also generated several criticisms from economists, as this practice has already caused the country to suffer from defaults in the past. In May 2023, Lula and Argentine president Alberto Fernández – a Peronist and Lula ally who while still a candidate had visited Lula in prison – in Brasília to discuss the economic crisis in Argentina as well as trade and energy between Argentina and Brazil. Lula stated that he has committed to make "each and every sacrifice so we can help Argentina in those hard times" including reaching out to both the IMF and the BRICS and that he will back up Brazilian exporters operating in the country. Lula welcomed Fernández in Brasília in June 2023 to celebrate the 200th anniversary of the establishment of diplomatic relations between Brazil and Argentina during which Fernández was rewarded with Brazil's highest award the Order of the Southern Cross.
=== Phase 1/2 === Dexmedetomidine (BXCL-501; Igalmi; KalmPen) – α2-adrenergic receptor agonist – opioid-related disorders Ibogaine (DMX-1002; IBX-210) – various actions/unknown mechanism of action and oneirogen/hallucinogen – opioid-related disorders 5-Methoxy-2-aminoindane (MEAI; 5-MeO-AI; CMND-100) – serotonin–norepinephrine releasing agent – alcoholism PT-00114 (PT100114; TCAP-1) – corticotropin-releasing hormone (CRH) inhibitor – opioid-related disorders
Sources: en.wikipedia.org
Lt. Col. J. H. Fuller (18 April 1909 – 1 April 1911) Maj. Gordon Vallancy Drury (1 April 1911 – 28 January 1913) Maj. Gen. Sir Alfred Hamilton Mackenzie Edwards (28 January 1913 – 23 January 1923) Col. Algernon Essex Capell (1 February 1923 – 11 February 1926) Alfred James Tomlinson (12 February 1926 – 12 May 1926; acting) Col. George Stops (13 May 1926 – 14 February 1933) Brig. John Sidney Morris (15 February 1933 – 24 April 1945) Brig. John Ellis "Jack" Ross (24 April 1945 – 6 December 1950) Col. James Appleby (7 December 1950 – 2 June 1954) Col. Arthur Selwyn Hickman (3 June 1954 – 5 November 1955) Col. Harold Jackson (6 November 1955 – 12 March 1958) Basil Gordon Spurling (13 March 1958 – 25 April 1963) Frank Eric Barfoot (26 April 1963 – 2 January 1968) James Spink (3 January 1968 – 26 June 1970) Sydney Frederick Samuel Bristow (27 June 1970 – 6 February 1974) Peter Dennis Wray Richard Sherren (7 February 1974 – 6 February 1978) Peter Kevin Allum (7 February 1978 – 6 February 1982)
Bophuthatswana (, lit. 'gathering of the Tswana people'), officially the Republic of Bophuthatswana (Tswana: Repaboleki ya Bophuthatswana; Afrikaans: Republiek van Bophuthatswana), colloquially referred to as the Bop and by outsiders as Jigsawland (In reference to its enclave-ridden borders) was a Bantustan (also known as "Homeland", an area set aside for members of a specific ethnicity) that was declared (nominally) independent by the apartheid regime of South Africa in 1977. However, like the other Bantustans of Ciskei, Transkei and Venda, its independence was not recognized by any country other than South Africa. Bophuthatswana was the second Bantustan to be declared an independent state by the Apartheid government, after Transkei. Its territory constituted a scattered patchwork of enclaves spread across what was then Cape Province, Orange Free State and Transvaal. Its seat of government was Mmabatho, which is now a suburb of Mahikeng. On 27 April 1994, it was reintegrated into South Africa with the coming into force of the country's interim constitution. Its territory was distributed between the new provinces of the Free State, Gauteng, Mpumalanga and North West Province.
=== Background === Before bitcoin, several digital cash technologies were released, starting with David Chaum's ecash in the 1980s. The idea that solutions to computational puzzles could have some value was first proposed by cryptographers Cynthia Dwork and Moni Naor in 1992. The concept was independently rediscovered by Adam Back who developed Hashcash, a proof-of-work scheme for spam control in 1997. The first proposals for distributed digital scarcity-based cryptocurrencies came from cypherpunks Wei Dai (b-money) and Nick Szabo (bit gold) in 1998. In 2004, Hal Finney developed the first currency based on reusable proof of work. These various attempts were not successful: Chaum's concept required centralized control and no banks wanted to sign on, Hashcash had no protection against double-spending, while b-money and bit gold were not resistant to Sybil attacks.
== Research == Since 2009 the Foundation has sponsored numerous clinical trials conducted by the Waterford Institute of Technology, and has funded numerous Fellowships, the principal bequest being a Chair in Human Nutrition funded permanently by it from October 2016, the current holder being Professor John Nolan PhD.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.